Immunome Q2 EPS $(0.60) Misses $(0.39) Estimate, Sales $2.36M Miss $2.55M Estimate
Portfolio Pulse from Benzinga Newsdesk
Immunome (NASDAQ:IMNM) reported Q2 earnings per share (EPS) of $(0.60), missing the analyst estimate of $(0.39) by 53.85%. Sales were $2.36M, also missing the estimate of $2.55M by 7.29%. Both EPS and sales showed significant declines compared to the same period last year.
August 12, 2024 | 8:02 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Immunome reported Q2 EPS of $(0.60), missing the analyst estimate of $(0.39) by 53.85%. Sales were $2.36M, missing the estimate of $2.55M by 7.29%. Both EPS and sales showed significant declines compared to the same period last year.
The significant miss on both EPS and sales estimates, along with the year-over-year declines, is likely to negatively impact investor sentiment and the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100